Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline

Several months after a splashy announcement, an ambitious pharmaceutical industry venture to tackle antibiotic resistance has hired its first chief executive officer and received $140 million in additional funding commitments.

The AMR Action Fund, which was organized with $1 billion in pledged funds from nearly two dozen drug makers, tapped Henry Skinner, a venture capitalist and the former head of Novartis (NVS) Venture Funds, to pilot the project.